3SOF

this could easily break out into the double digits today and most of this is just PPS correction,CLBE should be trading at .15 to .20's without any new info and BTW heres a e-mail from IR

Paul Knopick

The company tells me to expect a news release detailing achievements in
stem cell banking soon.

CLBE will be more then fine soon,this is not a PR pumpiong company and the last share holder letter should make that clear,not to many CEO's will post in public the opinions he has,it would be far too liable if he didn't think it would come to past.

The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.

Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.

We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.


 
    Sincerely, 
    James DeOlden 
    Chief Executive Officer 

CLBE - CalbaTech

these links should show everyone investing in CLBE just exactly what they are about and why they are going to increase in value tremendously.For those here who remember our pick of BIPH from .09 to .20's as a strong buy and it ran to $3.60 within a few months and TDCP from the subs to $3's within the same year CLBE is projected to reach $2 to $4 range in the not so distant future.DD it closely and my personal contact with Paul in IR says a PR is due out any time now on the opening of the new MicroBank for stem cell collections.CLBE is an adult stem cell med sector company and there is no unethical restrictions.

http://www.calbatech.com/

http://www.kdmedical.com/

http://www.molecula.com/

http://www.molecula.com/new/index2.html

http://www.solanamedspas.com/home_B.htm

http://www.biotechnologyireland.com/...Q=BF_COMP_9172

Adult, not embryonic, stem cells better for research

http://www.statenews.com/op_article.phtml?pk=36817


http://english.chosun.com/w21data/ht...510060016.html

Catholic Church Funds Adult Stem Cell Research

first link is a couple years old but gives crystal clear direction for now.

http://www.21stcenturysciencetech.co...stem_cell.html

BIOLOGY & MEDICINE

The Case for Adult Stem Cell Research

CLBE - CalbaTech

these links should show everyone investing in CLBE just exactly what they are about and why they are going to increase in value tremendously.For those here who remember our pick of BIPH from .09 to .20's as a strong buy and it ran to $3.60 within a few months and TDCP from the subs to $3's within the same year CLBE is projected to reach $2 to $4 range in the not so distant future.DD it closely and my personal contact with Paul in IR says a PR is due out any time now on the opening of the new MicroBank for stem cell collections.CLBE is an adult stem cell med sector company and there is no unethical restrictions.

http://www.calbatech.com/

http://www.kdmedical.com/

http://www.molecula.com/

http://www.molecula.com/new/index2.html

http://www.solanamedspas.com/home_B.htm

http://www.biotechnologyireland.com/...Q=BF_COMP_9172

Adult, not embryonic, stem cells better for research

http://www.statenews.com/op_article.phtml?pk=36817


http://english.chosun.com/w21data/ht...510060016.html

Catholic Church Funds Adult Stem Cell Research

first link is a couple years old but gives crystal clear direction for now.

http://www.21stcenturysciencetech.co...stem_cell.html

BIOLOGY & MEDICINE

The Case for Adult Stem Cell Research


*********** Msg from Ramsburg ***************
Please read the rules, this pick is not valid
******************************************

--------------------------------------------------------------------------------
http://www.thejournalnews.com/apps/pbcs.dll/article?AID=/20051018/OPINIO N01/510180321/1015

Stem-cell strategies   


(Original publication: October 18, 2005)



Scientists in separate experiments have obtained embryonic stem cells from mice without destroying an embryo. This could remove moral and ethical objections to using embryonic stem cells for medical research toward possible cures for Alzheimer's, diabetes, Parkinson's spinal injuries and other health problems.
Embryonic stem cells are master cells that can develop into any part of the body: skin, bone, muscle, brain. However, when the cells are extracted, the embryo dies. Opponents of embryonic stem-cell research call it murder; President Bush has blocked federal money from supporting new lines of embryonic stem-cell research.

Scientists at the Massachusetts Institute of Technology were able to extract stem cells from eggs that were gene-blocked from developing into an embryo. Dr. William Hurlbut, a member of the President's Council of Bioethics, has endorsed this method because the eggs cannot produce an embryo that will develop.

A study at Advanced Cell Technology, a Worcester, Mass., company, adapted a fertility clinic technique of removing a single cell from an embryo. While clinics use the cell to test for genetic disorders, the company used it to establish a stem-cell line. In both instances, the embryo goes on to develop.

Another breakthrough of sorts occurred in August, when a Harvard University team of scientists were able to fuse an embryonic stem cell and an adult skin cell. The stem cell reprogrammed the adult cell to revert to a stem cell. If scientists can learn how the stem cell changed the adult cell, it may be possible to reprogram adult cells without using stem cells. That goal, those involved said, may be five to 10 years away.

Privately funded embryonic stem-cell research is being done here as well as overseas. Research in adult stem cells is also being conducted. Some scientists contend that embryonic stem cells have better potential for medical treatments than adult cells.

If science can extract those cells without destruction of the embryo, that potential could be realized without the moral and ethical doubts that now hinder research.

--------------------------------------------------------------------------------
http://news.bbc.co.uk/1/hi/health/4348920.stm

"I think scientists would be far better to concentrate on other areas of stem cell research such as amniotic and adult stem cells which show far more promise"

------------------------------------------------------------------------ --------
http://www.ledger-enquirer.com/mld/ledgerenquirer/news/nation/12931252.h tm

Stem-cell researchers debate ethics of new methods

BY JEREMY MANIER

Chicago Tribune


CHICAGO - (KRT) - When researcher Rudolf Jaenisch started work earlier this year on a method of producing embryonic stem cells that would avoid ethical objections, one of his first hurdles was not scientific but personal: He did not believe there was any moral problem in the first place.

But practical considerations led Jaenisch and his team at the Massachusetts Institute of Technology to attempt the new stem cell extraction method, which they described in the journal Nature this week.

The need to destroy embryos to obtain stem cells has aroused powerful opposition to federal funding of such work. But Jaenisch thought if he could extract the cells without destroying a viable embryo, it might satisfy the opponents. And less controversy could mean more money for the field.

"I don't really have the objections that many people do have," Jaenisch said. "But you realize the realities in this country ... I think we need a compromise in this debate."

Jaenisch's report is one of two new studies in Nature that outline ways of making embryonic stem cells without destroying a viable embryo. Jaenisch harvested stem cells from a mouse embryo that was not viable: It was genetically altered so it could not develop in the womb. A separate group at Massachusetts-based Advanced Cell Technology was able to take cells from a normal mouse embryo without destroying it.

Some ethicists believe the work could help quell the uproar over federal funding of stem cell research, though others say the new methods are no better ethically than the techniques that caused the original objections.

That even the researchers involved are ambivalent illustrates the keen difficulty of finding common ground on the issue. William Hurlbut, a Stanford University bioethicist who first proposed the method that Jaenisch used, said the researchers are sincere in seeking a solution, though he acknowledged the irony of the situation.

"This is a strange moment in science, because scientists are trying to solve a problem that they don't feel is a problem," Hurlbut said.

In fact, Jaenisch voiced skepticism about the ethical merits of Hurlbut's idea during an interview with the Chicago Tribune in May. At that moment, Jaenisch now says, his own team already was trying to make the technique work.

The process involves altering a method of stem cell extraction called nuclear transfer, or therapeutic cloning.

In the original technique, researchers make an embryo by placing the nucleus of an adult cell in an egg cell that has been emptied of DNA. After an electric jolt, the egg begins dividing like an embryo, eventually forming a ball of cells that contains stem cells. Such cells can form any kind of tissue, offering the potential of new treatments for conditions such as Parkinson's disease and diabetes.

Hurlbut proposed altering this technique so that the ball of cells, called a blastocyst, cannot form a full-fledged person. Jaenisch's team did that in mice by silencing a gene called cdx2, which helps form the embryo's outer wall and, eventually, the placenta that keeps a fetus alive.

Such deficiencies, applied to human cells, would result in an entity with "a dramatically different developmental potential than a human embryo," Hurlbut said. Skeptics contend it would still be an embryo, albeit a damaged one.

In May, when the President's Council on Bioethics issued a report that contained some praise and criticism of Hurlbut's technique, Jaenisch agreed with many of the critics.

"Does being human or not depend on the state of one particular gene? That doesn't make sense," Jaenisch said.

Jaenisch still doesn't agree with the moral basis of the new technique, he said. But he said it was an interesting experiment that could provide a practical foundation for advancing the field.

The method doesn't solve any moral problem for Richard Doerflinger, deputy director of pro-life activities for the U.S. Conference of Catholic Bishops. In an e-mail response to questions, Doerflinger said taking out the cdx2 gene "seems to make a very damaged human embryo that cannot survive past a few days of development (instead of making a new entity that is not an embryo)."

Like Jaenisch, Robert Lanza, leader of the research team at Advanced Cell Technology, has long argued that embryonic stem cell research is morally acceptable as is.

Still, he said, "I regard the embryo with respect. If we can do this without offending anyone, fine."

a lot of focus is being put into adult stem cell issues and CLBE is right in the midst of it among other things (gotta a feeling we will be getting news involving the companies DNA research soon,a completely differant division)

Adult stem cell therapy tested (12.10.05)

A new project has been launched to discover whether a patient's own stem cells can be used to treat heart disease.

The study, funded by the Heart Cells Foundation, is being undertaken at the Barts and The London NHS Trust, where researchers will conduct a four-year study examining 700 patients.

Experts will use three different types of stem cell therapy techniques on three randomised control groups – the first made up of patients whose hearts are failing due to a previous heart attack; a group of patients suffering from dilated cardiomyopathy; and a group made up of patients who had just suffered a heart attack.

Doctors will extract stem cells from bone marrow in some patients' hips to inject into their major coronary artery or into their heart in a minimally invasive operation, while other patients will receive growth factor drugs to encourage their stem cells to spill out into the blood stream.

Lead researcher Dr Anthony Mathur said: "This is one of the biggest and most comprehensive trials of its kind in the world.

"Our studies will tell us if adult stem cells in bone marrow can repair damaged hearts and if so how these cells should be administered to patients. 

"There is growing evidence to suggest that stem cells may benefit people with serious heart conditions, such as heart failure or those who have had heart attacks."

The Heart Cells foundation was set up by Ian Rosenberg, who suffered from such severe heart disease he was given months to live, until he received stem cell therapy in Germany.

"Stem cell therapy has given me years I never thought I would have," he said.

"I set up the Heart Cells Foundation so that others may benefit from this new and exciting science."

http://www.ageconcern.org.uk/AgeConcern/News_MoreInfo.cfm?Articleid=1506 4655

http://www.calbatech.com/shareholder.pdf

Drug Week, 09/15/2005 07:18:31 PM EDT)

(Biotech Week, 09/15/2005 07:08:23 PM EDT)

(Medical Devices & Surgical Technology Week)


Biotech Week

CalbaTech, Inc., (CLBE) said its wholly owned subsidiary, K-D Medical, Inc., Columbia, Maryland, is acquiring a new facility that has two validated, Class 100 Clean Rooms for additional manufacture of products.

K-D Medical is a primary vendor to the National Institutes of Health (NIH) and currently sells products to every major pharmaceutical company in the U.S. K-D Medical's founder, John Powers, said the new Clean Rooms, plus a complete quality control laboratory, will allow the company to manufacture a higher quality product as well as expand the current custom product offering, better serving the needs of both existing and new customers.

"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers said.

"These new facilities allow K-D Medical to open new manufacturing and Clean Room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," said James DeOlden, chairman and CEO, CalbaTech. "We are very bullish on our subsidiary's future."

This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.

NewsRx.com) -- CalbaTech, Inc., (CLBE) has retained the services of Agora Investor Relations Corp. (Agora).

The objective of this agreement is two-fold. First, to create effective communication between CalbaTech, its shareholders and the investment community through Agora's Internet based investor relations system. Effective immediately, a customized and monitored CalbaTech IR HUB will allow both CalbaTech and Agora to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.

The IR HUB will also provide one-click access to the CalbaTech broker fact sheet, company profile, five most recent press releases, e-mail list registration, latest stock quote and chart information and an executive audio address updated quarterly. In addition, the IR HUB provides investors with a monitored discussion forum for the purposes of constructive and high-quality discussion about the company that is free of spam, bashing, hyping and profanity.

Second, Agora will be fully responsible for creating, implementing and executing an investor relations strategy, the consolidation of which will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.

CalbaTech CEO James DeOlden stated, "We believe that the time is right to begin an investor awareness program. CalbaTech has been executing its business plan, and given the company's recent developments and the excitement being generated in the life sciences Industry, we believe the time has now come to significantly increase our communications with shareholders and the investment community."

This article was prepared by Biotech Week editors from staff and other reports. Copyright 2005, Biotech Week via NewsRx.com.

CalbaTech's business strategy is establish shareholder value by creating a significant new niche market by providing research reagents, equipment and services to the pharmaceutical research market, primarily through acquisition of life science companies that share the following attributes: 1) They will be generating revenues; 2) They will be profitable; and 3) They will be suppliers of products and services into the pharmaceutical research market. Rather than produce pharmaceutical products that require more than $100 Million to reach the marketplace, CalbaTech companies will seek to provide the products and services used by the researchers creating pharmaceutical products.

Current subsidiaries of CalbaTech --

Molecula http://www.molecula.com/

KD Medical -- http://www.kdmedical.com/

MolecularWare format geneID files-- http://microarray.imb.uq.edu.au/printinfo/ Web site coming soon -- http://www.molecularware.com/

LifeStem.com recently registered -- http://www.domainsnext.com/comingsoonheader.php?domain=lifestem.com

CLBE web site -- http://www.calbatech.com/

"The company reported that its outside patent counsel has conducted a preliminary patent review of the concepts and has reported favorable findings to CalbaTech's management. LifeStem, Dr. Van Tassel and outside counsel will work to further refine the intellectual property and expect to file provisional patents with the United States Patent Office".

Also the fact that the stock ran to .20 in july, expenses static around 1-mil, and this news out Thurs., is significiant, only it may take a few weeks for everyone to sort out.

  this should be enough DD to spark an interest!

Date: Saturday, October 08, 2005 9:03:09 AM EST By STEVE MITCHELL, Senior Medical Correspondent

WASHINGTON, Oct. 8 (UPI) -- Researchers said Saturday they have used stem cells collected from the amniotic fluid surrounding fetal lambs to grow windpipes, and then implanted the tissue back into the fetuses while they were still in the womb -- a breakthrough that could lead to ways to repair congenital defects before birth.

Defects in the windpipe or trachea are rare in humans, but they can be life-threatening and are difficult to repair. Often, the fix -- involving surgery soon after birth -- can be fraught with complications, including brain damage.

Dr. Dario Fauza and colleagues at Children's Hospital in Boston hope their technique can offer a way around such problems by repairing the defect before the baby is born.

"The fetus doesn't need the trachea, so the repair would have time to heal in utero," Fauza said in a statement, "and fetal healing is very good -- it's better than adult healing."

The technique involves extracting amniotic fluid, which surrounds the fetus in the womb, to obtain a type of stem cells known as mesenchymal stem cells. These cells arise directly from embryonic stem cells and they can give rise to various cell types, so they could be used to regenerate damaged or diseased tissues.

http://www.menafn.com/qn_news_story.asp?StoryId=Cq0DeqeidDxmTzMv0DxnYzxbHAxi

Pro-Life Congressman and Dr. J Seek Adult Stem Cell Research Bill

Washington, DC (LifeNews.com) -- A leading pro-life congressman and former Philadelphia 76ers basketball star Julius "Dr. J" Erving teamed up at a press conference Thursday to ask the Senate to pass a House-approved bill that would promote adult stem cell research using umbilical cord blood.
The bill provides funding to use stem cells from umbilical cord blood, which have proven to be the most effective and the House approved HR 2520 434-1 in May.

The Senate has stalled on voting for the bill because it has gotten caught up in the divisive debate over using taxpayer funds for embryonic stem cell research. Smith asked that the Senate not delay any further on voting on the bill.

"Delay is denial, especially for the sick who will not benefit from cord blood transplantation because the Senate inexplicably delayed," Smith said. "Make no mistake, for these sick children and adults, this is a matter of life or death."

Dr. J, who is currently the Vice President of the Orlando Magic, said African American patients need the bill to be approved because they have a much lower chance to obtain a match within the current bone marrow and umbilical cord blood stem cell inventories.

"Each year, thousands of Americans die who could be saved if larger and more diverse inventories of umbilical cord stem cells were in existence," Erving noted. "I came today to join Congressman Smith in asking the Senate to finish the job and pass this legislation and provide doctors the resources they need to treat the thousands of courageous patients in desperate need of help."

Currently, some minorities have less than a 50% chance of obtaining a potentially life saving transplant

Umbilical cords are a rich, non-controversial source of stem cells. Currently hospitals throw millions of them away each year because the infrastructure required to properly collect and store them is not available.

Thousands havebeen successfully treated with cord blood stem cells for more than 67 diseases including Leukemia and Sickle Cell Anemia.

The infusion of federal funds will make this medical miracle available to thousands more and will ensure that research continues so that this source of stem cells can treat many other debilitating diseases.

Numerous doctors and patients who have been treated with umbilical cord stem cells also attended the press conference.

Boswell backs adult stem cell research

Medical studies into embryonic stem cells have failed and it was time to get behind alternative research, Nationals Senate leader Ron Boswell says.

Three years ago, after a passionate debate, federal parliament passed laws giving scientists access to unwanted human embryos for research purposes.

Since then the national scientific regulator has issued nine licences for such research.

But Senator Boswell told parliament on Wednesday the research had come to nothing and support should now be given to alternative research on adult stem cells.

"The last debate was a very difficult one for many of us and led to deep searching over ethical issues involved," Senator Boswell told parliament.

"My point is that for all the pain we went through, for all the cost, we are not even close to the promised cures from embryo research.

"Yet there is true hope out there that medical research will tackle the most painful and debilitating diseases known to humanity and it will do it through adult stem cell technology.

"The only question is how long before the world wakes up to it.

"We have before us a sober opportunity to change direction to a zone of scientific research that is free of ethical dilemmas."

Senator Boswell said research had shown that adult stem cells provided a viable alternative to embryonic stem cells.

He said researchers at Queensland's Griffith University had successfully grown adult stem cells harvested from the olfactory mucosa, the organ of smell in the human nose.

They demonstrated the cells can give rise not only to nerve cells but also to heart, liver, kidney, and muscle cells.

The research team, led by Professor Alan Mackay-Sim has spent the past four years developing the research, particularly investigating the potential of stem cells in treating Parkinsons disease.

Senator Boswell's speech came as Industry Minister Ian Macfarlane was planning a forum for federal MPs next week to consider the issues surrounding stem-cell technologies.

Mr Macfarlane warned earlier this week that Australia's reputation as a global player in biotechnology could be undermined if conservative forces succeeded in banning embryonic stem-cell research.

CLBE is acting just as BIPH did in its early stages when I posted it at .09,once it broke the last time it finally stayed on the climb (to $3.60 actually) and yes,it did make its dips,but buying back in was quite hard as it will be here.This is a strong buy and hold and put it away.I have been in contact with the company as recent as this past Saturday (yes Saturday,they even work on the weekend!..LOL)CalbaTech has a lot more going for them then many will realize until its to late and they will be chasing it.

GREAT biotech ,look at the chart history,this is a all time low pretty much and watching the news on the Adult stem cell technoque that is patent pending the Company has 39,561,205 shares of common stock issued and outstanding, of which 21,772,737 
were held by non-affiliates. 


About CalbaTech 

CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board, that intend to contribute innovation in areas of biological discovery. 

Contact: Paul Knopick (949) 707-5365 pknopick*eandecommunications.com

Been reading the most recent 10K, thought I'd share some of my favorite quotes:

1. "The company believes that it will report a net profit for 2005."

2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."

3. Officers and Directors:

James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.

Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.

John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.

4. Scientific Advisory Board:

Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.

Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.

Just thought I'd clarify that the Bush administration's objection to embryonic stem cell research should NOT hurt this company. In fact, it could help. I have read this administration's report on stem cell research (had to for class last year), and one of their objections to embryonic stem cells is that they feel adult stem cells offer similar advantages without the moral problems related to embryonic stem cells. In other words, the Bush administration supports the use of adult stem cells.The new method under development here is for living adult stem cell extraction!!I think this is going to launch much higher soon and if any news leaks get out on the patent concerning the adult stem cell extraction method this will go nuts,most people don't like the embryo extraction methods and controversy and this patent will remove that issue altogether!!

Catholic Church Funds Adult Stem Cell Research

The Catholic Church in Korea has decided to donate money for adult
stem cell research. The move comes amid strong Vatican opposition to
embryonic stem cell research and is reflects support for research
into an alternative.
The Church has been among the most vocal opponents of embryonic stem
cell research based on the belief that embryos are human beings. In
Korea, a country leading that field of science, the Catholic Church
is donating millions of dollars to aid research involving adult stem
cells in the hope of reducing the increasing reliance on embryonic
stem cells to treat hard-to-cure diseases.

"The research harms the integrity of life, and that's why we cannot
accept the use of embryos," the church said. It wants to fund
research on adult stem cells derived from bone marrow or umbilical
cords that would otherwise be discarded after a baby is born. They
say this is more practical and does not cause ethical controversy.

The Seoul Diocese set up a committee to donate W10 billion (US$10
million). The church said it will not assist the research of Korea's
Dr. Hwang Woo-suk who grabbed the world's attention last year by
announcing the successful cloning of a human embryo. Catholics have
criticized Hwang since his work involved using human eggs and
destroying embryos to harvest stem cell batches.

Embryonic stem cells have the potential to become any cell or tissue
of a human body like bone, skin or blood. In contrast, adult stem
cells, which can be harvested from adult patients, can only be used
to create specific cell types like muscle tissue from muscle stem
cells. The decision by the Seoul Diocese may still fuel an ongoing
debate between religious and academic groups over the desired type of
stem cell research.


15375 Barranca Parkway
Irvine, CA 92618 (Map)Phone: 949-450-9910
Fax: 949-450-9954
http://www.calbatech.com

CalbaTech now looks to build a portfolio by buying companies that
develop new technologies to sell or license; it also targets
universities that are planning to license technology developed in
academic labs. The firm is interested in products that will generate
sales or licensing revenue within two years and need less than $1
million. Among its acquisitions are MolecularWare and iStem
Technologies

MoleculareWare helps scientists have the wherewithal to keep their
As, Cs, Gs, and Ts straight. The firm, a subsidiary of CalbaTech,
offers bioinformatics software and other products to integrate the
volumes of data produced from high throughput screening,
combinatorial synthesis, and other methods of genomics research. Its
DigitalGENOME suite consists of three software programs. DesignerDG
can configure microplates and track the liquids used in the
microplate wells. AnalyzerDG analyzes images and manages data from
microarrays; the software can be used as part of DigitalGENOME or on
its own. IntegratorDG can integrate data stored in a variety of
database platforms, including platforms from Oracle and Microsoft.

these are just some brief bits of information concerning CalbaTech,its worth every second of your time to do some serious DD on this company.

at least the alert came out during the lunchtime lull!! best time to make entries is now becaise everyone gets the news after 2 imo.IMO target of .06 to .09

Emerging Stock Report: Paradigm Looking Forward Again
10/11/05

Oct 11, 2005 (M2 PRESSWIRE via COMTEX) --
The Emerging Stock Report is following Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB) up 57.3% today as it announced the completion of the settlement of the federal and state court class action lawsuits that were filed against the Company and its former executive officers, Thomas P. Motter, Mark M. Miehle, and John W. Hemmer.

Under the terms of settlement of the federal court class action lawsuit, U.S. Fire Insurance Company, which issued a Directors and Officers Liability and Company Reimbursement Policy to Paradigm Medical for the period from July 10, 2002 to July 10, 2003, agreed to pay the sum of $1,507,500 in cash to the class members that purchased securities of the Company during the period between April 17, 2002 and November 4, 2002. Under the terms of settlement of the state court class action lawsuit, U.S. Fire agreed to pay the sum of $625,000 in cash to the class members that purchased shares of Series E Convertible preferred stock on or about July 11, 2001.

Paradigm Medical Industries, Inc., currently develops, manufactures and markets surgical and diagnostic high-tech, proprietary equipment and consumable products for the medical industry. The company specializes in the development and marketing of diagnostic equipment for the ophthalmic market. These products include of topographers, autoperimeters and ultrasonic biomicroscopes and a unique Blood Flow Analyzer help the eye care professional's community diagnose and treat disorders of they eye such as glaucoma, cataracts and age-related macular degeneration. The Company's corporate offices are located in, Salt Lake City, Utah.

Recommended Guidelines for Eye Exams Before age 5:Toddlers should be screened for common childhood problems such as crossed eye, lazy eye, nearsightedness and farsightedness. From puberty to age 39 you should be checked if you experience any eye problems or visual changes such as pain, floaters, flashes of light, blurry vision, or eye injury. During ages 40 to 65 you should be examined every two to four years. Everyone over 65 should be examined every one to two years. People at higher risk for eye diseases need to be examined more often. For example, adults with diabetes should have yearly eye exams. Other people at higher risk include blacks over age 40, people with a family history of eye disease, or those with a history of eye injury.

Source: American Academy of Ophthalmology

Ian Birrell

The Emerging Stock Report profiles emerging growth companies and brings them to the attention of the investment community ahead of the market providing concise analysis and resources required in determining when a stock appears poised for growth.

Get a Complimentary Subscription at www.*********************** for your complimentary subscription.

Subscribers have access to investment research reports, tools for tracking and analyzing, current news, detailed company profiles and ESR "E-Alert" Services. ESR produces comprehensive, timely and dependable research available on the Internet.
_________________

AMEP is a given "gap and runner" Monday,this is my top OTC ONG pick based on fundamentals alone and not even ONG production and posted it throughout at .013's.

Look also at the Biotech pick and DD it...CLBE,I put some info in this forum and you will see anywhere under .20's will be a gift very soon.

bottomline is that nothing has changed at all,think about it,if we opened and traded normally today and we closed where we are now would anyone really be that concerned? The problem with today was this,looking back on the intraday it appears everyone wanted in this at open and right away,this of course caused an immediate jump in the PPS and then many raised their buys settings and chased it,the PPS rose more under buying pressure,now momo is in play tripping even more radars to buy in and then the DT's took exits and the MM's played right on it,they started dropping the bid support on wide spreads trying to panic traders (which worked for the most part) and stopped to momo in its tracks...all this in one day trading session.Many shares were bought today over .11,quite a bit actually,I even bought at multiple levels above there.Nothing has changed though,NG still going up and won't stop for a while,winters just about coming in and no NG production going on in the gulf,today was a fluke,this will be in the double digits again tomorrow and the traders will try and swing it again imo,lets hope the PR hits us after open!!

       GLTA

       Q